EADV 2026: Galderma's New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis - Iberonews

7 reports from 6 outlets in 1 language · first reported 2026-09-30 05:04 UTC · updated 2026-09-30 10:08 UTC · JSON

Reports

1. EADV 2026: Galderma's New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic DermatitisPublished by intelligencer.ca, recorder.ca, standard-freeholder.com, thewhig.com · 2026-09-30 05:04 UTC
2. EADV 2026: Galderma's New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis - Iberonewsiberonews.com · en · 2026-09-30 10:08 UTC
3. Galderma Reports Three-Year Nemluvio Data In Moderate-to-Severe Atopic Dermatitisrttnews.com · en · 2026-09-30 06:00 UTC
4. Galderma's Nemluvio Shows Sustained Three-Year Benefits In Atopic Dermatitisrttnews.com · en · 2026-09-30 05:44 UTC